Septerna (NASDAQ:SEPN) Rating Increased to Strong-Buy at Raymond James Financial

Raymond James Financial upgraded shares of Septerna (NASDAQ:SEPN) to a strong-buy rating in a research note released on Friday,Zacks.com reports.

A number of other research analysts have also commented on the stock. Truist Financial initiated coverage on shares of Septerna in a research note on Monday. They issued a “buy” rating and a $34.00 price objective on the stock. HC Wainwright raised their price target on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of Septerna in a research report on Friday, September 5th. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $18.00 to $28.00 in a research report on Friday, November 14th. Finally, Wall Street Zen raised Septerna from a “buy” rating to a “strong-buy” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Septerna presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Septerna Trading Up 7.4%

Shares of NASDAQ SEPN opened at $29.58 on Friday. The stock has a market cap of $1.32 billion, a P/E ratio of -19.59 and a beta of 3.80. Septerna has a twelve month low of $4.17 and a twelve month high of $30.50. The stock has a 50 day moving average of $23.76 and a two-hundred day moving average of $16.87.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The business had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. As a group, research analysts predict that Septerna will post -7.11 earnings per share for the current year.

Insider Transactions at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new stake in shares of Septerna in the 3rd quarter valued at approximately $36,000. Covestor Ltd grew its holdings in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after acquiring an additional 1,296 shares during the period. BNP Paribas Financial Markets raised its position in Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after acquiring an additional 1,945 shares in the last quarter. Deutsche Bank AG lifted its holdings in Septerna by 53.3% in the first quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock valued at $92,000 after acquiring an additional 5,549 shares during the period. Finally, PharVision Advisers LLC purchased a new stake in shares of Septerna during the 2nd quarter worth $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.